Molecular imaging in management of colorectal metastases by the interventional oncologist

References

• Siegel, RL, Miller, KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70:7–30.
   Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines for patients- colon cancer. 2018. Available from: https://www.nccn.org/patients/guidelines/content/PDF/colon-patient.pdf
   Google Scholar
• Ko C-C, Yeh L-R, Kuo Y-T, et al. Imaging biomarkers for evaluating tumor response: RECIST and beyond. Biomark Res. 2021;9:52.
   PubMed Web of Science ®Google Scholar
• Hunt SJ, Seraj SM, Alavi A. PET assessment of immune effects from interventional oncology procedures. PET Clin. 2019;14:477–485.
   PubMed Web of Science ®Google Scholar
• Lam MGEH, Hunt SJ, El-Haddad GE, et al. Evolving role of PET in interventional Radiology-Based oncology procedures. PET Clin. 2019;14:xiii–xxiv.
   PubMed Web of Science ®Google Scholar
• Expert Panel on Gastrointestinal Imaging:, Fowler KJ, Kaur H, et al. ACR appropriateness criteria® pretreatment staging of colorectal cancer. J Am Coll Radiol. 2017;14:S234–S244.
   PubMed Web of Science ®Google Scholar
• Maffione AM, Lopci E, Bluemel C, et al. Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging. 2015;42:152–163.
   PubMed Web of Science ®Google Scholar
• Petersen RK, Hess S, Alavi A, et al. Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy. Am J Nucl Med Mol Imaging. 2014;4(5):471–482.
   PubMedGoogle Scholar
• Ozis SE, Soydal C, Akyol C, et al. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the primary staging of rectal cancer. World J Surg Oncol. 2014;12:26.
   PubMed Web of Science ®Google Scholar
• Ruers TJM, Wiering B, van der Sijp JRM, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med. 2009;50(7):1036–1041.
   PubMed Web of Science ®Google Scholar
• Berger KL, Nicholson SA, Dehdashti F, et al. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol. 2000;174(4):1005–1008.
   PubMed Web of Science ®Google Scholar
• Bae SU, Won KS, Song B-I, et al. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer. Cancer Imaging. 2018;18(1):32.
   PubMedGoogle Scholar
• Dahmarde H, Parooie F, Salarzaei M. Is 18F-FDG PET/CT an accurate way to detect lymph node metastasis in colorectal cancer: a systematic review and Meta-Analysis. Contrast Media Mol Imaging. 2020;2020:5439378.
   PubMed Web of Science ®Google Scholar
• Daza JF, Solis NM, Parpia S, et al. A Meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastases. Eur J Surg Oncol. 2019;45(8):1341–1348.
   PubMed Web of Science ®Google Scholar
• Serrano PE, Gu C-S, Moulton C-A, et al. Effect of PET-CT on disease recurrence and management in patients with potentially resectable colorectal cancer liver metastases. Long-term results of a randomized controlled trial. J Surg Oncol. 2020;121(6):1001–1006.
   PubMed Web of Science ®Google Scholar
• Arslan E, Aksoy T, Gürsu RU, et al. The prognostic value of 18F-FDG PET/CT and KRAS mutation in colorectal cancers. Mol Imaging Radionucl Ther. 2020;29(1):17–24.
   PubMed Web of Science ®Google Scholar
• Kawada K, Toda K, Nakamoto Y, et al. Relationship between 18F-FDG PET/CT scans and KRAS mutations in metastatic colorectal cancer. J Nucl Med. 2015;56(9):1322–1327.
   PubMed Web of Science ®Google Scholar
• Shady W, Petre EN, Vakiani E, et al. Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget. 2017;8(39):66117–66127.
   PubMedGoogle Scholar
• Popovic M, Talarico O, van den Hoff J, et al. KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver. EJNMMI Res. 2020;10(1):142.
   PubMed Web of Science ®Google Scholar
• Gulec SA, Suthar RR, Barot TC, et al. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging. 2011;38:1289–1295.
   PubMed Web of Science ®Google Scholar
• Edalat F, Camacho JC, Kokabi N, et al. Standardized added metabolic activity predicts survival after intra-arterial resin-based 90Y radioembolization therapy in unresectable chemorefractory metastatic colorectal cancer to the liver. Clin Nucl Med. 2016;41:e76–e81.
   Web of Science ®Google Scholar
• Levy EB, Fiel MI, Hamilton SR, et al. State of the art: toward improving outcomes of lung and liver tumor biopsies in clinical trials-A multidisciplinary approach. J Clin Oncol. 2020;38(14):1633–1640.
   PubMed Web of Science ®Google Scholar
• Tatli S, Gerbaudo VH, Mamede M, et al. Abdominal masses sampled at PET/CT-guided percutaneous biopsy: initial experience with registration of prior PET/CT images. Radiology. 2010;256:305–311.
   PubMed Web of Science ®Google Scholar
• Kishore SA, Drabkin MJ, Sofocleous CT. Fluorodeoxyglucose-PET for ablation treatment planning, intraprocedural monitoring, and response. PET Clin. 2019;14:427–436.
   PubMed Web of Science ®Google Scholar
• Venkatesan AM, Kadoury S, Abi-Jaoudeh N, et al. Real-time FDG PET guidance during biopsies and radiofrequency ablation using multimodality fusion with electromagnetic navigation. Radiology. 2011;260:848–856.
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Ikeda O, Kawanaka K, et al. Comparison of CT-guided percutaneous biopsy with and without registration of prior PET/CT images to diagnose mediastinal tumors. Cardiovasc Intervent Radiol. 2014;37:1306–1311.
   PubMed Web of Science ®Google Scholar
• Lei P, Dandekar O, Widlus D, et al. Incorporation of preprocedural PET into CT-guided radiofrequency ablation of hepatic metastases: a nonrigid image registration validation study. J Digit Imaging. 2010;23:780–792.
   PubMed Web of Science ®Google Scholar
• Guralnik L, Rozenberg R, Frenkel A, et al. Metabolic PET/CT-guided lung lesion biopsies: impact on diagnostic accuracy and rate of sampling error. J Nucl Med. 2015;56:518–522.
   PubMed Web of Science ®Google Scholar
• Klaeser B, Mueller MD, Schmid RA, et al. PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences. Eur Radiol. 2009;19(7):1780–1785.
   PubMed Web of Science ®Google Scholar
• Aparici CM, Aslam R, Win AZ. Initial experience of utilizing real-time intra-procedural PET/CT biopsy. J Clin Imaging Sci. 2014;4:54.
   PubMedGoogle Scholar
• Cornelis F, Silk M, Schoder H, et al. Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities. Eur J Nucl Med Mol Imaging. 2014;41(12):2265–2272.
   PubMed Web of Science ®Google Scholar
• Cornelis FH, Petre EN, Vakiani E, et al. Immediate postablation 18F-FDG injection and corresponding SUV are surrogate biomarkers of local tumor progression after thermal ablation of colorectal carcinoma liver metastases. J Nucl Med. 2018;59(9):1360–1365.
   PubMed Web of Science ®Google Scholar
• Fanchon LM, Dogan S, Moreira AL, et al. Feasibility of in situ, high-resolution correlation of tracer uptake with histopathology by quantitative autoradiography of biopsy specimens obtained under 18F-FDG PET/CT guidance. J Nucl Med. 2015;56(4):538–544.
   PubMed Web of Science ®Google Scholar
• Kirov AS, Fanchon LM, Seiter D, et al. Technical note: ccintillation well counters and particle counting digital autoradiography devices can be used to detect activities associated with genomic profiling adequacy of biopsy specimens obtained after a low activity 18 F-FDG injection. Med Phys. 2018;45(5):2179–2185.
   PubMed Web of Science ®Google Scholar
• Sainani NI, Shyn PB, Tatli S, et al. PET/CT-guided radiofrequency and cryoablation: is tumor fluorine-18 fluorodeoxyglucose activity dissipated by thermal ablation? J Vasc Interv Radiol. 2011;22:354–360.
   PubMed Web of Science ®Google Scholar
• Shyn PB, Casadaban LC, Sainani NI, et al. Intraprocedural ablation margin assessment by using ammonia perfusion PET during FDG PET/CT-guided liver tumor ablation: a pilot study. Radiology. 2018;288(1):138–145.
   PubMed Web of Science ®Google Scholar
• Ryan ER, Sofocleous CT, Schöder H, et al. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology. 2013;268(1):288–295.
   PubMed Web of Science ®Google Scholar
• Cornelis F, Sotirchos V, Violari E, et al. 18F-FDG PET/CT is an immediate imaging biomarker of treatment success after liver metastasis ablation. J Nucl Med. 2016;57:1052–1057.
   PubMed Web of Science ®Google Scholar
• Shyn PB, Cubre AJ, Catalano PJ, et al. F-18 FDG perfusion PET: intraprocedural assessment of the liver tumor ablation margin. Abdom Radiol (NY). 2021;46:3437–3447.
   PubMed Web of Science ®Google Scholar
• Maas M, Beets-Tan R, Gaubert J-Y, et al. Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice. Insight Imaging. 2020;11(1):83.
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–359.
   PubMed Web of Science ®Google Scholar
• Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):55–66.
   PubMedGoogle Scholar
• Maas M, Rutten IJG, Nelemans PJ, et al. What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis : imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2011;38(8):1560–1571.
   PubMed Web of Science ®Google Scholar
• Nielsen K, van Tilborg AAJM, Scheffer HJ, et al. PET-CT after radiofrequency ablation of colorectal liver metastases: suggestions for timing and image interpretation. Eur J Radiol. 2013;82:2169–2175.
   PubMed Web of Science ®Google Scholar
• Kuehl H, Antoch G, Stergar H, et al. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol. 2008;67:362–371.
   PubMed Web of Science ®Google Scholar
• Sahin DA, Agcaoglu O, Chretien C, et al. The utility of PET/CT in the management of patients with colorectal liver metastases undergoing laparascopic radiofrequency thermal ablation. Ann Surg Oncol. 2012;19:850–855.
   PubMed Web of Science ®Google Scholar
• Bonichon F, Palussière J, Godbert Y, et al. Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2013;40:1817–1827.
   PubMed Web of Science ®Google Scholar
• Szyszko T, Al-Nahhas A, Canelo R, et al. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun. 2007;28(1):15–20.
   PubMed Web of Science ®Google Scholar
• Zerizer I, Al-Nahhas A, Towey D, et al. The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging. 2012;39:1391–1399.
   PubMed Web of Science ®Google Scholar
• Sabet A, Meyer C, Aouf A, et al. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. Eur J Nucl Med Mol Imaging. 2015;42(3):370–376.
   PubMed Web of Science ®Google Scholar
• Michl M, Lehner S, Paprottka PM, et al. Use of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancer. J Nucl Med. 2016;57(3):355–360.
   PubMed Web of Science ®Google Scholar